Impact of immortal person-time and time scale in comparative effectiveness research for medical devices: a case for implantable cardioverter-defibrillators-Reference-Cited by-同舟云学术

Impact of immortal person-time and time scale in comparative effectiveness research for medical devices: a case for implantable cardioverter-defibrillators

Published:2013-08 Issue:8 Volume:66 Page:S138-S144
ISSN:0895-4356
Container-title:Journal of Clinical Epidemiology
language:en
Short-container-title:Journal of Clinical Epidemiology

Author:

Mi Xiaojuan,Hammill Bradley G.,Curtis Lesley H.,Greiner Melissa A.,Setoguchi Soko

Publisher

Elsevier BV

Subject

Epidemiology

Reference29 articles.

1. Immortal time bias in pharmacoepidemiology;Suissa;Am J Epidemiol,2008

2. Observation and inference: an introduction to the methods of epidemiology;Walker,1991

3. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes;Levesque;BMJ,2010

4. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis;Renoux;Ann Neurol,2008

5. Immortal time bias in observational studies of drug effects;Suissa;Pharmacoepidemiol Drug Saf,2007

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between neuromuscular blocking agent use and outcomes among out-of-hospital cardiac arrest patients treated with extracorporeal cardiopulmonary resuscitation and target temperature management: A secondary analysis of the SAVE-J II study;Resuscitation Plus;2023-12

2. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation at low risk of stroke in japan: a retrospective cohort study;European Heart Journal - Cardiovascular Pharmacotherapy;2023-10-19

3. More intensive therapy has a better effect for frail parents with multiple myeloma;Blood Advances;2023-10-13

4. Suspected bias in selection criteria of target subpopulation and its validation;Critical Care;2023-07-12

5. Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb);Therapeutic Advances in Medical Oncology;2023-01